1. Epidemiology and Global Health
  2. Medicine

Cardiovascular disease and subsequent risk of psychiatric disorders: a nationwide sibling-controlled study

  1. Qing Shen  Is a corresponding author
  2. Huan Song
  3. Thor Aspelund
  4. Jingru Yu
  5. Donghao Lu
  6. Jóhanna Jakobsdóttir
  7. Jacob Bergstedt
  8. Lu Yi
  9. Patrick Sullivan
  10. Arvid Sjölander
  11. Weimin Ye
  12. Katja Fall
  13. Fang Fang
  14. Unnur Valdimarsdóttir
  1. Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Sweden
  2. Centre of Public Health Sciences, Faculty of Medicine, University of Iceland, Iceland
  3. West China Biomedical Big Data Center, West China Hospital, Sichuan University, China
  4. Medical Big Data Center, Sichuan University, China
  5. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Sweden
  6. Department of Epidemiology, Harvard T.H. Chan School of Public Health, United States
  7. Departments of Genetics and Psychiatry, University of North Carolina, United States
  8. Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Sweden
https://doi.org/10.7554/eLife.80143
Share this article
Cite this article
  1. Qing Shen
  2. Huan Song
  3. Thor Aspelund
  4. Jingru Yu
  5. Donghao Lu
  6. Jóhanna Jakobsdóttir
  7. Jacob Bergstedt
  8. Lu Yi
  9. Patrick Sullivan
  10. Arvid Sjölander
  11. Weimin Ye
  12. Katja Fall
  13. Fang Fang
  14. Unnur Valdimarsdóttir
(2022)
Cardiovascular disease and subsequent risk of psychiatric disorders: a nationwide sibling-controlled study
eLife 11:e80143.
https://doi.org/10.7554/eLife.80143
  2. Download BibTeX
  3. Download .RIS

Abstract

Background:

The association between cardiovascular disease (CVD) and selected psychiatric disorders has frequently been suggested while the potential role of familial factors and comorbidities in such association has rarely been investigated.

Methods:

We identified 869,056 patients newly diagnosed with CVD from 1987 to 2016 in Sweden with no history of psychiatric disorders, and 910,178 full siblings of these patients as well as 10 individually age- and sex-matched unrelated population controls (N = 8,690,560). Adjusting for multiple comorbid conditions, we used flexible parametric models and Cox models to estimate the association of CVD with risk of all subsequent psychiatric disorders, comparing rates of first incident psychiatric disorder among CVD patients with rates among unaffected full siblings and population controls.

Results:

The median age at diagnosis was 60 years for patients with CVD and 59.2% were male. During up to 30 years of follow-up, the crude incidence rates of psychiatric disorder were 7.1, 4.6, and 4.0 per 1000 person-years for patients with CVD, their siblings and population controls. In the sibling comparison, we observed an increased risk of psychiatric disorder during the first year after CVD diagnosis (hazard ratio [HR], 2.74; 95% confidence interval [CI], 2.62–2.87) and thereafter (1.45; 95% CI, 1.42–1.48). Increased risks were observed for all types of psychiatric disorders and among all diagnoses of CVD. We observed similar associations in the population comparison. CVD patients who developed a comorbid psychiatric disorder during the first year after diagnosis were at elevated risk of subsequent CVD death compared to patients without such comorbidity (HR, 1.55; 95% CI, 1.44–1.67).

Conclusions:

Patients diagnosed with CVD are at an elevated risk for subsequent psychiatric disorders independent of shared familial factors and comorbid conditions. Comorbid psychiatric disorders in patients with CVD are associated with higher risk of cardiovascular mortality suggesting that surveillance and treatment of psychiatric comorbidities should be considered as an integral part of clinical management of newly diagnosed CVD patients.

Funding:

This work was supported by the EU Horizon 2020 Research and Innovation Action Grant (CoMorMent, grant no. 847776 to UV, PFS, and FF), Grant of Excellence, Icelandic Research Fund (grant no. 163362-051 to UV), ERC Consolidator Grant (StressGene, grant no. 726413 to UV), Swedish Research Council (grant no. D0886501 to PFS), and US NIMH R01 MH123724 (to PFS).

Editor's evaluation

Whether a diagnosis of cardiovascular disease (CVD) increases risks of psychiatric disorders is not well understood. Using a large population-based case-sibling study in Sweden, this important study suggests that patients diagnosed with CVD are at higher risk of psychiatric disorders, independent of familial factors shared between full siblings and comorbid conditions. While the analysis is solid, additional variables that relate to both CVD risk and mental health need to be incorporated in follow-up analyses.

https://doi.org/10.7554/eLife.80143.sa0

Introduction

Being diagnosed and living with a major life-threatening disease is stressful and associated with multiple biologic processes that, when combined, may contribute to the development of psychiatric disorders. It is for instance demonstrated that a cancer diagnosis is associated with subsequent risk of psychiatric disorders (Lu et al., 2016) and self-inflicted injury (Shen et al., 2016), which in turn might be associated with a compromised cancer survival (Zhu et al., 2017). Psychiatric comorbidities have also been reported among patients with cardiovascular disease (CVD), for example, stroke (Lindén et al., 2007), heart failure (Rutledge et al., 2006), and myocardial infarction (Thombs et al., 2006; Shemesh et al., 2004), with indications of elevated risk of overall mortality (Doering et al., 2010; Wrenn et al., 2013). Yet, evidence on the association between CVD and subsequent development of psychiatric disorders is still limited as previous research has mainly relied on selected patient populations instead of complete follow-up of general population as well as limited control of reverse causality and important confounding factors, for example, familial factors and comorbidities (Lincoln et al., 2013; Morrison et al., 2005; Romanelli et al., 2002).

We thoroughly searched the existing literature on the association between CVD and clinically confirmed psychiatric disorders or psychiatric symptoms. After excluding most studies with either cross-sectional or retrospective designs, we only found 12 prospective cohort studies investigating the risk of selected psychiatric disorders following a diagnosis of CVD (Supplementary file 1a). While these prospective studies suggest a positive association of hypertension, heart disease, and stroke with depressive symptoms (Morrison et al., 2005; Wium-Andersen et al., 2017; Baccaro et al., 2019; Pohjasvaara et al., 2001) and stress-related disorders (Chang et al., 2017), they were limited to elderly populations (Petersson et al., 2014; Zhang et al., 2015), and used self-reported ascertainment of psychiatric outcomes (Petersson et al., 2014; Zhang et al., 2015) Only few of these studies addressed incident or first diagnosed psychiatric disorders among patients with CVD, for example, excluding patients with history of psychiatric disorders, and no study addressed the issue of familial confounding. Indeed, genetic correlation has recently been document between these two complex disease groups (Barnett and Smoller, 2009; Kathiresan and Srivastava, 2012; Rødevand et al., 2021) as well as the importance of early life environment for the development of both CVD (Kelishadi and Poursafa, 2014) and psychiatric disorders (Rokita et al., 2018). It is therefore unknown to what extent the reported association between CVD and psychiatric disorder can be explained by unmeasured confounding shared within families (Barnett and Smoller, 2009; Kathiresan and Srivastava, 2012; Rødevand et al., 2021). Thus, a comprehensive evaluation of the association between all CVDs and risk of any incident psychiatric disorder, addressing the abovementioned shortcomings, is warranted.

With up to 30 years of follow-up and with nationwide complete information on family links in Sweden, we aimed to investigate the association between CVD diagnosed in specialist care and subsequent risk of incident psychiatric disorders while accounting for familial factors through a sibling comparison. We further aimed to estimate the potential role of psychiatric comorbidity in cardiovascular mortality among patients with CVD.

Materials and methods

Study design

Request a detailed protocol

The Swedish Patient Register contains national information on inpatient care with complete coverage since 1987 and outpatient specialized care since 2001 (Ludvigsson et al., 2011). The Swedish Multi-Generation Register includes nearly complete familial information for Swedish residents born since 1932 (Ekbom, 2011). Using personal identification numbers assigned to all Swedish residents, we identified all individuals born in Sweden after 1932 who received a first diagnosis of any CVD and attended inpatient or outpatient specialized care between January 1, 1987 and December 31, 2016 (N = 986,726). Patients diagnosed with CVD before age 5 (N = 6091, probable congenital heart disease) or with a history of any psychiatric disorder before the diagnosis of CVD (N = 111,579) were excluded, leaving 869,056 patients in the analysis (Supplementary file 2). Date of first CVD diagnosis was used as the index date for the exposed patients.

We constructed a sibling-controlled matched cohort to control for familial confounding according to guidelines for designing family-based studies (D’Onofrio et al., 2013). Through the Multi-Generation Register, we identified all full siblings of patients with CVD (58.6% of all CVD patients) who were alive and free of CVD and psychiatric disorder at the time when their affected sibling was diagnosed (N = 910,178). In addition, for each patient with CVD, we randomly selected 10 age- and sex-matched individuals from the general population who were free of CVD or psychiatric disorder when the index patient was diagnosed (N = 8,690,560). The date of CVD diagnosis for the index patient was used as the index date for their unaffected siblings and matched population controls.

All study participants were followed from the index date until first diagnosis of any psychiatric disorder, death, emigration, first diagnosis of CVD (for unaffected siblings and matched population controls), or the end of the study period (December 31, 2016), whichever occurred first.

Ascertainment of CVD and psychiatric disorder

Request a detailed protocol

We defined CVD as any first inpatient or outpatient hospital visit with CVD as the primary diagnosis from the Swedish Patient Register. Incident psychiatric disorder was defined as any first inpatient or outpatient hospital visit with psychiatric disorder as the primary diagnosis. We used the 9th and 10th Swedish revisions of the International Classification of Diseases (ICD-9 and 10) codes to identify CVD and psychiatric disorders and their subtypes (Supplementary file 1b). In line with previous study (Song et al., 2019), we classified CVD as ischemic heart disease, cerebrovascular disease, emboli/thrombosis, hypertensive disease, heart failure, and arrhythmia/conduction disorder. We classified psychiatric disorders as non-affective psychotic disorders, affective psychotic disorders, alcohol or drug misuse, mood disorders excluding psychotic symptoms, anxiety and stress-related disorders, eating disorders, and personality disorders (Nevriana et al., 2020).

Covariates

Request a detailed protocol

We extracted socioeconomic information for each participant, including educational level, individualized family income, and cohabitation status, from the Longitudinal Integration Database for Health Insurance and Labor Market (Longitudinell integrationsdatabas för sjukförsäkrings- och arbetsmarknadsstudier (LISA), 2018). Missing information on socioeconomic status was categorized as unknown or missing group. A history of somatic diseases was defined as having any of the following conditions before the index date: chronic pulmonary disease, connective tissue disease, diabetes, renal diseases, liver disease, ulcer diseases, malignancies, and HIV infection/AIDS (Supplementary file 1b). We defined a family history of psychiatric disorders as a diagnosis of any psychiatric disorder among biological parents and full siblings of the study participants before the index date according to the Swedish Patient Register.

Statistical analysis

Request a detailed protocol

We used flexible parametric survival models to estimate the time-varying association between CVD and subsequent risk of incident psychiatric disorders (Lambert and Royston, 2009), by comparing the rates of incident psychiatric disorders in CVD patients with the corresponding rates in their unaffected full siblings and matched population controls. As we observed a marked risk increase of psychiatric disorders immediately following the CVD diagnosis, we separately assessed the association within 1 year of CVD diagnosis and beyond 1 year. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were derived from stratified Cox regression models, using time since the index date as the underlying time scale. We estimated HRs for any psychiatric disorder and categories of psychiatric disorders. We performed subgroup analyses by sex, age at index date (<50, 50–60, or >60 years), age at follow-up (<60 or ≥60 years), history of somatic diseases (no or yes), and family history of psychiatric disorder (no or yes). We also performed subgroup analysis by calendar year at index date (1987–1996, 1997–2006, or 2007–2016) to check for potentially different associations over time (i.e., due to lifestyle factors that changed over time, including smoking and alcohol use) (Sundin and Willner, 2007). In the sibling comparison, all Cox models were stratified by sibling sets and adjusted for sex, birth year, educational level, individualized family income, cohabitation status, and history of somatic diseases. In the population comparison, all Cox models were stratified by the matching variables birth year and sex and adjusted for all abovementioned covariates plus family history of psychiatric disorder.

To study the impact of additional cardiovascular comorbidity (i.e., patients with another type of CVD after diagnosis of the first CVD), we analyzed the association by the presence or absence of cardiovascular comorbidity after the index date according to the type of first CVD. This analysis was restricted to follow-up beyond 1 year to focus on patients who survived their first CVD to be able to receive the diagnosis of another CVD. As a patient with CVD might have different types of CVD, we identified all diagnoses of CVD during follow-up and considered CVD comorbidity as a time-varying variable through splitting the person-time according to each diagnosis.

Because the Swedish Patient Register includes only information related to specialist care, we might have misclassified patients with a history of milder psychiatric disorders diagnosed before index date attended only in primary care. To account for the reverse causality of having undetected psychiatric disorders or symptoms before the incident CVD, we performed a sensitivity analysis additionally excluding study participants with prescribed use of psychotropic drugs before the index date (ascertained from the Swedish Prescribed Drug Register including information on all prescribed medication use in Sweden since July 2005), and followed the remaining participants during 2006–2016. Use of psychotropic drugs during follow-up was also considered as having psychiatric disorder in this analysis.

To study rate of cardiovascular mortality (ascertained from the Swedish Causes of Death Register) in relation to psychiatric comorbidities after CVD diagnosis, we estimated Kaplan–Meier survival curves beyond the first year of follow-up for CVD patients with or without a diagnosis of psychiatric disorder during the first year of follow-up, separately. We estimated the survival curves by types of first diagnosed CVD as well as by types of psychiatric comorbidities. In addition to this 1-year time window, we also studied 6 months or 2 years since CVD diagnosis, to assess the robustness of these survival curves. We calculated the HRs of cardiovascular mortality for these two groups of patients using Cox model. To account for potential impact of unmeasured confounding due to lifestyle factors, we performed a sensitivity analysis excluding individuals with a history of alcoholic cirrhosis of liver (ICD-10 code K703) or chronic obstructive pulmonary disease (COPD, ICD-10 code J44), as proxies for heavy drinking or smoking.

Analyses were performed in STATA 17.0 (StataCorp LP). All tests were two sided and p < 0.05 was considered statistically significant. The study was approved by the Ethical Vetting Board in Stockholm, Sweden (DNRs 2012/1814-31/4 and 2015/1062-32).

Role of the funding source

Request a detailed protocol

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Results

The median age at index date was 60 years for CVD patients and 55 years for their unaffected full siblings (Table 1). 59.2% of the CVD patients and 48.4% of their unaffected siblings were male. CVD patients were more likely to have a history of somatic diseases than their unaffected siblings and matched population controls (15.6% vs. 8.8% and 11.0%). The most common diagnoses among the CVD patients were ischemic heart diseases (24.5%), arrhythmia/conduction disorders (24.2%), and hypertensive diseases (17.3%). The majority of the CVD patients had only one CVD diagnosis (without additional CVD comorbidities) during follow-up (69.7%).

Table 1
Characteristics of CVD patients diagnosed in Sweden between 1987 and 2016, their unaffected siblings and matched population controls.
CharacteristicsSibling comparisonPopulation comparison
CVD patients (N = 509,467)Unaffected full siblings (N = 910,178)CVD patients (N = 869,056)Matched population controls (N = 8,690,560)
Median age at index date in years (IQR)57 (48–65)55 (46–63)60 (51–68)60 (51–68)
Median follow-up time in years (IQR)8.1 (3.7–13.7)8.1 (3.8–13.7)7.7 (3.3–13.2)7.1 (3.2–12.4)
Male sex308,203 (60.5)440,177 (48.4)514,388 (59.2)5,143,880 (59.2)
Educational level
 <9 years149,555 (29.4)261,752 (28.8)272,960 (31.4)2,294,482 (26.4)
 9–12 years225,548 (44.3)413,702 (45.5)376,917 (43.4)3,548,338 (40.8)
 >12 years134,364 (26.4)234,724 (25.8)219,179 (25.2)2,847,740 (32.8)
Yearly individualized family income level
 Top 20%107,990 (21.2)175,658 (19.3)139,098 (16.0)1,757,726 (20.2)
 Middle301,706 (59.2)549,842 (60.4)535,109 (61.6)5,152,938 (59.3)
 Lowest 20%99,485 (19.5)184,588 (20.3)192,858 (22.2)1,706,931 (19.6)
 Unknown286 (0.1)90 (0.0)1991 (0.2)72,965 (0.8)
Cohabitation status
 Non-cohabitating223,134 (43.8)392,256 (43.1)373,337 (43.0)3,744,116 (43.1)
 Cohabitating286,047 (56.2)517,832 (56.9)493,728 (56.8)4,873,479 (56.1)
 Missing286 (0.1)90 (0.0)1991 (0.2)72,965 (0.8)
History of somatic disease*71,273 (14.0)79,679 (8.8)135,473 (15.6)955,030 (11.0)
Family history of psychiatric disorder†133,094 (26.1)251,237 (27.6)209,957 (24.2)2,003,161 (23.1)
Type of first-onset CVD
 Ischemic heart disease122,084 (24.0)–212,737 (24.5)–
 Cerebrovascular disease71,030 (13.9)–126,860 (14.6)–
 Emboli and thrombosis25,338 (5.0)–42,857 (4.9)–
 Hypertensive disease89,818 (17.6)–150,337 (17.3)–
 Heart failure15,726 (3.1)–30,469 (3.5)–
 Arrhythmia/conduction disorder126,738 (24.9)–210,654 (24.2)–
 Others58,733 (11.5)–95,142 (11.0)–
Number of cardiovascular diagnoses during follow-up
 One365,266 (71.7)–605,615 (69.7)–
 Two99,921 (19.6)–179,472 (20.7)–
 Three or more44,280 (8.7)–83,969 (9.7)–
  1. *

    History of somatic diseases included chronic pulmonary disease, connective tissue disease, diabetes, renal diseases, liver diseases, ulcer diseases, and HIV infection/AIDS that diagnosed before index date.

  2. †

    The difference between exposed patients and unaffected full siblings was due to different number of siblings for exposed patients. The family history of psychiatric disorder was constant within each family.

  3. IQR: interquartile range. CVD: cardiovascular disease.

During up to 30 years of follow-up, the crude incidence rates of psychiatric disorder were 7.1, 4.6, and 4.0 per 1000 person-years among CVD patients, their unaffected full siblings, and matched population controls, respectively (Supplementary file 1c). Compared with unaffected siblings, CVD patients showed an elevated risk of incident psychiatric disorder, especially immediately after diagnosis (Figure 1). The risk increase declined rapidly within the first few months after diagnosis and decreased gradually thereafter: the HR was 2.74 (95% CI, 2.62–2.87) within first year and 1.45 (95% CI, 1.42–1.48) beyond first year (Supplementary file 1d). The risk increment was noted in all types of psychiatric disorders within and beyond first year of follow-up (Figure 2 and Supplementary file 1e). Overall, the observed positive association was similar in sibling and population comparisons, although the HR of non-affective psychotic disorders beyond 1 year of CVD diagnosis was smaller in the sibling comparison than in the population comparison. During the entire follow-up, we found similar positive associations across sex, age at index date, age at follow-up, history of somatic diseases, and family history of psychiatric disorders (Supplementary file 1c). A greater risk increment was observed in recent calendar years than earlier years.

Figure 1
Download asset Open asset
Time-varying hazard ratios for an incident psychiatric disorder among CVD patients, compared with their unaffected full siblings (sibling comparison) or matched population controls (population comparison), by time of follow-up (<1 and ≥1 year from CVD diagnosis)*.

(A) Sibling comparison. (B) Population comparison. *CVD: cardiovascular disease. Time-varying hazard ratios and 95% confidence intervals were derived from flexible parametric survival models, allowing the effect of psychiatric disorder to vary over time. A spline with 5 df was used for the baseline rate, and 3 df was used for the time-varying effect. All models were adjusted for age at index date, sex, educational level, yearly individualized family income, cohabitation status, history of somatic diseases, as well as family history of psychiatric disorder (for population comparison). P<0.05 was considered level of significance.

Figure 2
Download asset Open asset
Hazard ratios with 95% confidence intervals for different types of psychiatric disorder among CVD patients compared with their full siblings and matched population controls, by time of follow-up (<1 or ≥ 1 year from CVD diagnosis)*.

*CVD: cardiovascular disease. Cox regression models were stratified by family identifier for sibling comparison or matching identifier (birth year and sex) for population comparison, controlling for age at index date, sex, educational level, individualized family income, cohabitation status, history of somatic diseases, and family history of psychiatric disorder (in population comparison). Time since index date was used as underlying time scale. P<0.05 was considered level of significance.

We found a higher risk of incident psychiatric disorder among all groups of CVD patients, with the most marked risk elevation observed among patients with cerebrovascular disease and heart failure (Figure 3 and Supplementary file 1f). A greater risk increment of incident psychiatric disorder was noted among CVD patients with additional cardiovascular comorbidities beyond 1 year of first CVD diagnosis compared with CVD patients without such comorbidities, except among those with heart failure (Figure 3—figure supplement 1). We found a similar positive association between CVD and risk of incident psychiatric disorder, when including use of psychotropic drugs as a definition of psychiatric disorder (Supplementary file 1g).

Figure 3 with 1 supplement see all
Download asset Open asset
Hazard ratios with 95% confidence intervals for psychiatric disorders among different groups of CVD patients compared with their full siblings and matched population controls, by time of follow-up (<1 or ≥ 1 year from CVD diagnosis)*.

*CVD: cardiovascular disease. Cox regression models were stratified by family identifier for sibling comparison or matching identifier (birth year and sex) for population comparison, controlling for age at index date, sex, education level, individualized family income, cohabitation status, history of somatic diseases, and family history of psychiatric disorder (in population comparison). Time since index date was used as underlying time scale. We identified all cardiovascular diagnoses during follow-up and considered CVD comorbidity as a time-varying variable by grouping the person-time according to each diagnosis. P<0.05 was considered level of significance.

CVD patients diagnosed with subsequent psychiatric disorder showed a lower CVD-specific survival compared with patients without such diagnosis (Figure 4 and Figure 4—figure supplement 1). The HR of CVD death was 1.55 (95% CI 1.44–1.67) when comparing CVD patients with a diagnosis of psychiatric disorder to patients without such diagnosis (mortality rate, 9.2 and 7.1 per 1 000 person-years, respectively). The compromised CVD-specific survival differed by types of CVD, and was most pronounced for hypertensive disease, ischemic heart disease, and arrhythmia/conduction disorder (Figure 4—figure supplement 2). When studying categories of psychiatric disorders, we found that the compromised survival among CVD patients was confined to those with comorbid non-affective and affective psychotic disorders, as well as alcohol or drug misuse (Figure 4—figure supplement 3).

Figure 4 with 3 supplements see all
Download asset Open asset
Estimated Kaplan–Meier curves of CVD death in CVD patients with and without incident psychiatric disorder during the first year of follow-upa.

aCVD: cardiovascular disease. Time since index date was used as underlying time scale. 90.4% of CVD patients (N = 785,287) survived the first year of follow-up and included in this analysis. P<0.05 was considered level of significance.

Discussion

Our large population-based sibling-controlled cohort study including all patients diagnosed with first-onset CVD between 1987 and 2016 in Sweden, their unaffected full siblings, as well as a set of randomly selected unaffected population controls reveals a robust association between CVD and subsequent risk of incident psychiatric disorder. We found that patients with CVD were at elevated risk of various types of psychiatric disorders, independent of confounding factors shared within families and history of somatic diseases. The risk increment was greatest during the year after CVD diagnosis, indicating an opportunity for clinical surveillance in a high-risk time window. Further, an occurrence of psychiatric comorbidity after CVD diagnosis was associated with an approximately 55% higher risk of subsequent death from cardiovascular causes. This finding further underscores the importance of surveillance and, if needed, treatment of psychiatric comorbidities among newly diagnosed CVD patients.

Comparison with other studies

Our findings are consistent with the existing literature suggesting a positive association between CVD and different types of psychiatric disorders. In previous studies, an increased risk of depression (Wium-Andersen et al., 2017; Baccaro et al., 2019; Pohjasvaara et al., 2001) and anxiety (Morrison et al., 2005) was noted after diagnosis of stroke (Morrison et al., 2005; Wium-Andersen et al., 2017; Baccaro et al., 2019; Pohjasvaara et al., 2001), hypertension (Petersson et al., 2014), coronary artery disease (Rutledge et al., 2013), and atrial fibrillation (Baumgartner et al., 2018). Such risk elevations have been suggested to be persistent over time (Lincoln et al., 2013; Zawadzka and Domańska, 2014; Berg et al., 2003), and, in parallel with our findings, associated with compromised survival (Doering et al., 2010; Cai et al., 2019; Bodén et al., 2015). However, the evidence from prospective cohort studies with a long and complete follow-up as well as with a thorough control of confounding factors and comorbid conditions has, up to this point, been limited. Our study therefore complements previous findings revealing a positive association between a broader range of CVDs and subsequent risk of incident psychiatric disorder, using a large cohort with control of various confounding factors. We found the association to be robust both in sibling and population comparisons, and after additional adjustment for various comorbidities including other additional CVDs, indicating that the association is unlikely explained by shared familial factors and various comorbidities. In addition to common psychiatric disorders, the evidence on CVD and other psychiatric disorders, for example, eating disorder, is limited. Our study therefore provides valuable indication on this association that deserves further research attention. We showed that CVD patients with psychiatric comorbidity were associated with an increased risk of subsequent CVD death, highlighting the importance of surveillance and prevention on psychiatric comorbidities for the newly diagnosed CVD patients. The associations remained similar after excluding individuals with liver cirrhosis and COPD, as proxies for heavy alcohol consumption and smoking, suggesting that residual confounding due to unmeasured lifestyle factors might not have overly substantial impact on the results.

The association between CVD and psychiatric disorders was noted both in men and women, across all age groups and calendar periods, as well as among individuals with or without a history of somatic diseases and family history of psychiatric disorders. Previous studies have indicated that major depression was more commonly recognized among individuals with multimorbidity (more than one CVD diagnosis) than those with only one condition (Findley et al., 2011). In our study, about 30% of the CVD patients developed one or more cardiovascular comorbidities during follow-up, and a higher risk of psychiatric disorder was indeed noted among patients with multiple CVD diagnoses. A compromised survival from CVD cause was indeed observed among most patients with common types of first CVD diagnosis and comorbid with psychiatric disorder, in particular among patients with hypertensive disease, ischemic heart disease, and arrhythmia/conduction disorder. Thus, particular clinical attention is needed for CVD patients with comorbid psychiatric disorders, particularly alcohol or drug misuse or psychotic disorders.

Potential mechanisms

The pathophysiological mechanisms linking CVD and psychiatric disorders are complex and not well understood, and may vary with specific diagnoses of CVD and psychiatric disorders. The highly increased risk noted immediately after CVD diagnosis may indicate a direct impact of stress reaction of being diagnosed with a life-threatening disease (Fang et al., 2012). In addition, it has been proposed that biological alterations in the cardiovascular system to a severe stress response may increase the risk of various psychiatric disorders (Levine et al., 2021). For example, cardiovascular risk factors including hypercoagulability, dyslipidemia, and an impaired immune response have been associated with impaired psychological health (Levine et al., 2021). Some biological changes in patients with coronary heart disease (e.g., decreased heart rate variability, increased arterial stiffness, and endothelial dysfunction) have been observed in patients with depressive and anxiety disorders (Sherwood et al., 2005; Seldenrijk et al., 2011; Stein et al., 2000). Chronic inflammation may induce the development of atherosclerosis and arterial thrombosis, and elevation in inflammatory biomarkers (i.e., IL-6 and C-reactive protein) has been reported in various psychiatric disorders including post-traumatic stress disorder and major depression (Libby, 2006; Sumner et al., 2020; Miller and Raison, 2016). Other behavioral and psychosocial factors may as well interact with these pathways and need to be understood further.

Strengths and limitations

The strengths of our study include its large sample size of the entire Swedish nation and the prospective study design with sibling comparison that significantly alleviates concerns of familial confounding from shared genetic and environmental factors between siblings. The Swedish population and health registers provide the opportunity to obtain complete follow-up as well as the prospectively and independently collected information on disease identification, minimizing the risk of selection and information biases. The large sample size of our study further enables detailed subgroup analyses by types of CVD, types of psychiatric disorders, and patient characteristics.

Some limitations need to be acknowledged. First, we identified patients with CVD and psychiatric disorder through inpatient or outpatient hospital visit. The later inclusion of outpatient records in the Swedish Patient Register may lead to underestimation of the actual numbers of patients with CVD and psychiatric disorder, especially those with relatively milder symptoms. Second, we missed individuals attending primary care only, which may underestimate the proportion of individuals with history of psychiatric disorders at cohort entry. To alleviate such concerns, we additionally considered the use of prescribed psychotropic drugs as a proxy of psychiatric disorders and found similar results. Further, patients with CVD have an established contact with health care and may therefore be more likely than others to be diagnosed with psychiatric disorder. Although such surveillance bias may to some extent explain the increased risks during the first few months after CVD diagnosis, it is unlikely that the risk elevation during the entire follow-up is attributed to such bias. Finally, although we found similar results with and without excluding individuals with a history of liver cirrhosis or COPD, as proxies for heavy drinking or smoking (Supplementary file 1h). We did not have direct access to hazardous behaviors that could potentially modify this association, and therefore cannot exclude the possibility of residual confounding.

Conclusions

Using a large population-based sibling-controlled cohort with up to 30 years of follow-up, we found patients with CVD are at elevated risk of newly diagnosed psychiatric disorder, independent of familial background shared between siblings, history of somatic diseases, and other cardiovascular comorbidities. Our study further observes higher cardiovascular mortality among CVD patients with subsequent psychiatric comorbidities, providing evidence for increased surveillance of psychiatric comorbidity among newly diagnosed patients with CVD.

Data availability

Data analyses were performed in STATA 17.0 (StataCorp LP). STATA script used in the primary analyses has been made available as supplementary appendix. Aggregated data used for generating figures are available in supplementary appendix. The original data used in this study are owned by the Swedish National Board of Health and Welfare and Statistics Sweden. The authors are not able to make the dataset publicly available according to the Public Access to Information and Secrecy Act in Sweden. Any researchers (including international researchers) interested in accessing the data can send request to the authorities for data application by: (1) apply for ethical approval from local ethical review board; (2) contact the Swedish National Board of Health and Welfare (https://bestalladata.socialstyrelsen.se/, email: registerservice@socialstyrelsen.se) and/or Statistics Sweden (https://www.scb.se/vara-tjanster/bestall-data-och-statistik/, email: scb@scb.se) with the ethical approval and submit a formal application for access to register data. The same contacts can be used for detailed information about how to apply for access to register data for research purposes.

References

  40. Book
    1. Sundin J
    2. Willner S
    (2007)
    Social Change and Health in Sweden
    Swedish National Institute of Public Health.

Decision letter

  1. Prabhat Jha
    Reviewing Editor; University of Toronto, Canada
  2. Eduardo Franco
    Senior Editor; McGill University, Canada
  3. Rajini Nagrani
    Reviewer; Leibniz Institute for Prevention Research and Epidemiology - BIPS, Germany

Our editorial process produces two outputs: (i) public reviews designed to be posted alongside the preprint for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.

Decision letter after peer review:

Thank you for submitting your article "Cardiovascular disease and subsequent risk of psychiatric disorders: a nationwide sibling-controlled study" for consideration by eLife. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor (Prabhat Jha) and Eduardo Franco as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Rajini Nagrani (Reviewer #2).

The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission. Please review each comment carefully.

Essential revisions:

1) Address reverse causality, namely if a psychiatric illness (PI) developed before or about the same time as the CVD. The much steeper risk relationships early after a CVD event are so suggestive.

2) Could adjusting for matched factors in such cohort studies re-introduce bias into these estimates?

3) Address the point about the choice of preselecting exposure (CVD) group, rather than depicting the nationwide cohort of general population followed up for a disease outcome with each category having exposed and unexposed individuals.

4). Realign discussion such that the strength and limitations are the penultimate section of discussion along with reducing the definitive tone of the conclusions.

5). Authors are suggested to redo the flowchart such that the controls and cases are presented at the same level. At the moment it gives an impression that the comparison group (both population and sibling) is a subgroup of the CVD patients group.

6). Align the abstract, introduction, and discussion with the lack of lifestyle data, which would encompass several key potential confounders (notably smoking and alcohol use). Without it, it seems likely that there is a high risk of substantial confounding. It would be helpful if the authors adjusted the language to more accurately reflect this throughout, such as removing allusions to causal inference and tempering statements about adjustment for confounders where appropriate. This would include discussion specifically of alcohol and smoking risks in the Swedish population over time.

7). One of the main findings is that psychiatric disorder comorbidity diagnosed after cardiovascular disease diagnosis was associated with an increased risk of CVD-related mortality (such as shown in Figure 4). There needs to be more discussion of the potential relevance of cardiovascular disease or psychiatric disorder subtype in this relationship, both in the results and the Discussion sections. Intuitively, it would be expected that more severe cardiovascular diseases are associated with higher stress and a greater risk of psychiatric disorders. As such, the greater rate of mortality in those diagnosed with psychiatric disorders may largely be reflective of the initial cardiovascular diagnosis rather than having much to do with the psychiatric disorder diagnosis. Supplementary Figure 4 suggests that different subtypes of cardiovascular disease may have different relationships between psychiatric disorder diagnosis and survival rate, but this doesn't appear to be touched on at all in the results or the discussion.

8). Relatedly, could you please present similar analyses to Supplementary Figure 4 showing different survival curves by psychiatric subtype instead of cardiovascular subtype?

Reviewer #2 (Recommendations for the authors):

1. Authors are suggested to realign the discussion such that the strength and limitations are the penultimate sections of the discussion.

2. Authors are suggested to redo the flowchart such that the controls and cases are presented at the same level. At the moment it gives an impression that the comparison group (both population and sibling) is a subgroup of the CVD patients group.

Reviewer #3 (Recommendations for the authors):

1. As described in the public review, I feel the current version of the manuscript does not quite align at places in the abstract, introduction, and discussion with the lack of lifestyle data, which would encompass several key potential confounders. Without it, it seems likely that there is a high risk of substantial confounding. It would be helpful if the authors adjusted the language to more accurately reflect this throughout, such as removing allusions to causal inference and tempering statements about adjustment for confounders where appropriate.

2. One of the main findings is that psychiatric disorder comorbidity diagnosed after cardiovascular disease diagnosis was associated with an increased risk of CVD-related mortality (as shown in Figure 4). There needs to be more discussion of the potential relevance of cardiovascular disease or psychiatric disorder subtype in this relationship, both in the results and the Discussion sections. Intuitively, it would be expected that more severe cardiovascular diseases are associated with higher stress and a greater risk of psychiatric disorders. As such, the greater rate of mortality in those diagnosed with psychiatric disorders may largely be reflective of the initial cardiovascular diagnosis rather than having much to do with the psychiatric disorder diagnosis. Supplementary Figure 4 suggests that different subtypes of cardiovascular disease may have different relationships between psychiatric disorder diagnosis and survival rate, but this doesn't appear to be touched on at all in the results or the discussion.

3. Relatedly, could you please present similar analyses to Supplementary Figure 4 showing different survival curves by psychiatric subtype instead of cardiovascular subtype?

https://doi.org/10.7554/eLife.80143.sa1

Author response

Essential revisions:

1) Address reverse causality, namely if a psychiatric illness (PI) developed before or about the same time as the CVD. The much steeper risk relationships early after a CVD event are so suggestive.

Thank you for the comment. Previous studies have consistently reported an association between psychiatric disorders and CVD [1,2], thus, we agree that reverse causality may, in principle, explain some of the observed results indicating a rise in incident psychiatric disorders after incident CVD, particularly during the immediate period. Yet, it is reasonable to assume that a diagnosis of a lifethreatening disease, such as CVD, is in many cases a traumatic experience resulting in an immediate rise in risks of psychiatric disorders. Others have reported such associations e.g. after natural disasters and we have indeed observed such a pattern in our previous work, e.g., after cancer diagnosis [3]. However, we agree that reverse causality cannot be excluded and may partly contribute to the highly increased risk of psychiatric disorder immediately after CVD diagnosis. Indeed, some of these patients may have been attended for their psychiatric disorders in primary care before the incident CVD. As the Patient Register only captures in- and outpatient hospital care, we have conducted an additional analysis, also excluding individuals with previous prescriptions of psychotropic drugs (ATC codes: N05, N06) before their incident CVD – thereby adding a detection of patients with prevalent mental health problems attended by primary care. The results show similar point estimates (Supplementary File 1g) thus not supporting the notion that reverse causality is a major concern. Furthermore, the association is noted up to 28 years after CVD diagnosis, which is unlikely due to reverse causality.

We have now added our motivation for this additional analysis on the Method (Page 9), as below.

“Because the Swedish Patient Register includes only information related to specialist care, we might have misclassified patients with a history of milder psychiatric disorders diagnosed before index date attended only in primary care. To account for the reverse causality of having undetected psychiatric disorders or symptoms before the incident CVD, we performed a sensitivity analysis additionally excluding study participants with prescribed use of psychotropic drugs before the index date (ascertained from the Swedish Prescribed Drug Register including information on all prescribed medication use in Sweden since July 2005), and followed the remaining participants from 2006 to 2016.”

2) Could adjusting for matched factors in such cohort studies re-introduce bias into these estimates?

Thank you for the comment. Adjusting for matching factors should provide estimates with the same validity as using a stratified model. In our study, we matched individuals diagnosed with a CVD with their unaffected full siblings as well as 10 randomly selected, unexposed individuals, on the same age and sex, without such diagnosis. As controlling for matching variables is recommended when there are additional confounders [1,2], we used a stratified Cox model commonly applied in family-based studies [3,4].

References:

1. Sjölander A, Greenland S. Ignoring the matching variables in cohort studies – when is it valid and why? Stat Med. 2013 Nov 30;32(27):4696-708.

2. Mansournia MA, Hernán MA, Greenland S. Matched designs and causal diagrams. Int J Epidemiol. 2013 Jun;42(3):860-9.

3. D'Onofrio BM, Lahey BB, Turkheimer E, Lichtenstein P. Critical need for family-based, quasi-experimental designs in integrating genetic and social science research. Am J Public Health. 2013 Oct;103 Suppl 1(Suppl 1):S46-55.

4. Song, H., Fang, F., Arnberg, F. K., Mataix-Cols, D., de la Cruz, L. F., Almqvist, C., … and Valdimarsdóttir, U. A. (2019). Stress related disorders and risk of cardiovascular disease: population based, sibling controlled cohort study. bmj, 365.

3) Address the point about the choice of preselecting exposure (CVD) group, rather than depicting the nationwide cohort of general population followed up for a disease outcome with each category having exposed and unexposed individuals.

Thank you for the comment. As correctly pointed out by the reviewer, we used a matched cohort design, both in the population- and sibling comparison. We firstly identified a nationwide cohort of general population who were born after 1932 and were residing in Sweden 1987-2016. We then identified all exposed individuals with first-ever diagnosis of CVD and matched population controls from this same nationwide population.

A matched cohort design is applied here due to the strong confounding effects of some variables, e.g., age and sex, on the studied association between CVD and risk of psychiatric disorder. Exact matching on age and sex in our study makes the exposed and unexposed groups comparable and relief the confounding effects from matching factors in the design phase. Another practical viewpoint for why we use a matched cohort is a straightforward understanding of the comparison between exposed and unexposed groups being always at the same time, providing measures (such as risks and rates) during the follow-up period that are easily interpreted. Further, we have used this matched cohort design in many of our previous works [1,2] to maintain an identical design in both sibling and population comparison, so that the point estimates can be directly compared. The matched cohort design generates results of equal validity of the more conventional cohort design suggested by the reviewer [3] but has the additional quality of making the results from the various cohorts (here: population- and sibling comparison) more comparable. Our study therefore takes advantage of using a siblingcontrolled matched cohort, which is indeed a cohort design recommended for family-based studies [4] and provides results with similar validity as a full cohort.

We have now added a sentence and a reference in Method to motivate the use of matched cohort design (Page 7).

“We constructed a sibling-controlled matched cohort to control for the familial confounding according to guidelines for designing family-based studies.24”

We have now updated the flowchart to add a box in the top reflecting the source population where both groups were identified from, shown in Supplementary File 2.

References:

1. Song H, Fang F, Arnberg FK, Mataix-Cols D, Fernández de la Cruz L, Almqvist C, Fall K, Lichtenstein P, Thorgeirsson G, Valdimarsdóttir UA. Stress related disorders and risk of cardiovascular disease: population based, sibling controlled cohort study. BMJ. 2019 Apr 10;365:l1255.

2. Song H, Fang F, Tomasson G, Arnberg FK, Mataix-Cols D, Fernández de la Cruz L, Almqvist C, Fall K, Valdimarsdóttir UA. Association of Stress-Related Disorders With Subsequent Autoimmune Disease. JAMA. 2018 Jun 19;319(23):2388-2400.

3. Sjölander A, Greenland S. Ignoring the matching variables in cohort studies–when is it valid and why?. Statistics in medicine. 2013 Nov 30;32(27):4696-708.

4. D'Onofrio BM, Lahey BB, Turkheimer E, Lichtenstein P. Critical need for family-based, quasi-experimental designs in integrating genetic and social science research. Am J Public Health. 2013 Oct;103 Suppl 1(Suppl 1):S46-55.

4). Realign discussion such that the strength and limitations are the penultimate section of discussion along with reducing the definitive tone of the conclusions.

Thank you for the suggestion. We have now moved Strengths and Limitation section before the conclusion paragraph, as suggested (Pages 16-17).

We have now modified conclusions by removing definite terms such as “demonstrate”, “indicate”, and “increased”.

The modified conclusion:

Page 17: “Using a large population-based sibling-controlled cohort with up to thirty years of followup, we found patients with CVD are at elevated risk of newly diagnosed psychiatric disorder, independent of familial background shared between siblings, history of somatic diseases, and other cardiovascular comorbidities. The study further observes higher cardiovascular mortality among CVD patients with subsequent psychiatric comorbidities, providing evidence for increased surveillance of psychiatric comorbidity among newly diagnosed patients with CVD.”

5). Authors are suggested to redo the flowchart such that the controls and cases are presented at the same level. At the moment it gives an impression that the comparison group (both population and sibling) is a subgroup of the CVD patients group.

Thank you for the suggestion. Please note that the design is a sibling cohort but not a sibling case control study. We have now updated the flowchart presenting the matched population controls as well as unexposed siblings at the same level with their CVD patients, shown in Supplementary File 2.

6). Align the abstract, introduction, and discussion with the lack of lifestyle data, which would encompass several key potential confounders (notably smoking and alcohol use). Without it, it seems likely that there is a high risk of substantial confounding. It would be helpful if the authors adjusted the language to more accurately reflect this throughout, such as removing allusions to causal inference and tempering statements about adjustment for confounders where appropriate. This would include discussion specifically of alcohol and smoking risks in the Swedish population over time.

Thank you for the comment. We have now modified the text throughout, by removing causal terms.

In Abstract

Page 3, remove “halted causal inferences” and replaced with: “The association between cardiovascular disease (CVD) and selected psychiatric disorders has frequently been suggested while the potential role of familial factors and comorbidities in such association has rarely been investigated.”

Page 3, replaced “increased” with “higher”.

In Introduction, Page 5-6:

Removed “firmly”;

Replaced “a rapid rise” to “subsequent risk of”;

Replaced “attributed to” to “explained by”;

Remove “comprehensively”;

As the reviewer points out, we do recognize the potential unmeasured influence of lifestyle factors (e.g. smoking and alcohol consumption) on the studied associations as these data are not collected in registries. Sibling comparison can control for shared familial factors including lifestyles developed in early life. However, residual confounding from lifestyle factors not shared within siblings may still exist. In our study, the associations between CVD and psychiatric disorders were quite stable across calendar time, although somewhat stronger by the end of the observation period. The evidence does not suggest a drastic change in lifestyle factors in Sweden during the latter part of the observation period except for a slight increase in alcohol consumption [1,2] and liver cirrhosis [3]. Although we find it implausible that such underlying secular trends in lifestyle are a major contributor in the reported associations, we have now conducted additional analyses, excluding individuals with alcoholic cirrhosis of liver (ICD-10 code: K70.3) or COPD (chronic obstructive pulmonary disease, ICD-10 code: J44) as a proxy for heavy drinking or smoking. The results remained virtually unchanged.

We have now added reasons for stratified analysis by calendar years in Method (Pages 8-9):

“We performed subgroup analyses by sex, age at index date (<50, 50-60, or >60 years), age at follow-up (<60 or ≥60 years), history of somatic diseases (no or yes), and family history of psychiatric disorder (no or yes). We also performed subgroup analysis by calendar year at index date (1987-1996, 1997-2006, or 2007-2016) to check for potentially different associations over time (i.e., due to lifestyle factors that changed over time, including smoking and alcohol use).”

We found similar associations between first-onset CVD and incident psychiatric disorder with and without excluding individuals with a history of alcoholic cirrhosis of liver or COPD, used as a proxy for heavy drinking or smoking. The table has now added as Supplementary File 1h.

We have now added justifications in Method (Page 10) and in Discussion (Page 14 and Page 16-17), and as below: In method, Page 10:

“To account for potential impact of unmeasured confounding due to lifestyle factors, we performed a sensitivity analysis excluding individuals with a history of alcoholic cirrhosis of liver (ICD-10 code K703) or chronic obstructive pulmonary disease (COPD, ICD-10 code J44), as proxies for heavy drinking or smoking.”

In Discussion Page 14:

“The associations remained similar after excluding individuals with liver cirrhosis and COPD, as proxies for heavy alcohol consumption and smoking.”

Page 16-17:

“although we found similar results with and without excluding individuals with a history of liver cirrhosis or COPD, as proxies for heavy drinking or smoking (Supplementary File 1h). We did not have direct access to hazardous behaviors that could potentially modify this association, and therefore cannot exclude the possibility of residual confounding.”

References:

1. Statista. https://www.statista.com/statistics/693505/per-capita-consumption-of-alcohol-in-thenordic-countries/. Retrieved on 19 Aug.

2. Alcohol and Drug Report. Nordic Baltic Region. https://www.nordicalcohol.org/swedenconsumption-trends. Retrieved on 19 Aug.

3. Gunnarsdottir SA, Olsson R, Olafsson S, Cariglia N, Westin J, Thjódleifsson B, Björnsson E.Liver ;cirrhosis in Iceland and Sweden: incidence, aetiology and outcomes. Scandinavian journal of gastroenterology. 2009 Jan 1;44(8):984-93.

7). One of the main findings is that psychiatric disorder comorbidity diagnosed after cardiovascular disease diagnosis was associated with an increased risk of CVD-related mortality (such as shown in Figure 4). There needs to be more discussion of the potential relevance of cardiovascular disease or psychiatric disorder subtype in this relationship, both in the results and the Discussion sections. Intuitively, it would be expected that more severe cardiovascular diseases are associated with higher stress and a greater risk of psychiatric disorders. As such, the greater rate of mortality in those diagnosed with psychiatric disorders may largely be reflective of the initial cardiovascular diagnosis rather than having much to do with the psychiatric disorder diagnosis. Supplementary Figure 4 suggests that different subtypes of cardiovascular disease may have different relationships between psychiatric disorder diagnosis and survival rate, but this doesn't appear to be touched on at all in the results or the discussion.

Thank you for the comment. We agree that Supplementary Figure S4 indicates varying degree of compromised survival in relation to psychiatric disorders for different types of CVD.

We have now elaborated this in Results (Page 13) and Discussion (Page 15).

In Results, Page 13:

“The compromised CVD-specific survival differed by type of CVD, and was most pronounced for hypertensive disease, ischemic heart disease, and arrhythmia/conduction disorder compared to other CVDs (Figure 4 —figure supplement 2).”

In Discussion, Page 15:

“A compromised survival from CVD cause was indeed observed among most patients with common types of first CVD diagnosis and comorbid with psychiatric disorder, in particular among patients with hypertensive disease, ischemic heart disease, and arrhythmia/conduction disorder. Thus, particular clinical attention is needed for CVD patients with comorbid psychiatric disorders, particularly alcohol or drug misuse or psychotic disorders.”

8). Relatedly, could you please present similar analyses to Supplementary Figure 4 showing different survival curves by psychiatric subtype instead of cardiovascular subtype?

Thank you for the suggestion. We added, as suggested, a Figure 4 —figure supplement 3, showing the survival curves according to types of incident psychiatric disorder. A compromised survival was noted among CVD patients comorbid with non-affective and affective psychotic disorders, as well as alcohol or drug misuse.

We have now added this new analysis in Methods (10), Results (Page 13) and Discussion (Page 15).

In Methods, Page 10:

“We estimated the survival curves by types of first CVD types as well as by types of psychiatric comorbidities.”

In Results, Page 13:

“When studying categories of psychiatric disorders, we found that the compromised survival among CVD patients was confined to those with comorbid non-affective and affective psychotic disorders, as well as alcohol or drug misuse (Figure 4 —figure supplement 3).”

In Discussion, Page 15:

“Thus, particular clinical attention is needed for CVD patients with comorbid psychiatric disorders, particularly alcohol or drug misuse or psychotic disorders.”

Reviewer #2 (Recommendations for the authors):

1. Authors are suggested to realign the discussion such that the strength and limitations are the penultimate sections of the discussion.

Thank you for the suggestion. We have now moved Strengths and Limitation section before the conclusion paragraph, as suggested (Pages 16-17).

2. Authors are suggested to redo the flowchart such that the controls and cases are presented at the same level. At the moment it gives an impression that the comparison group (both population and sibling) is a subgroup of the CVD patients group.

Thank you for the suggestion. Please note that the design is a sibling cohort but not a sibling case control study. We have now updated the flowchart presenting the matched population controls as well as unexposed siblings at the same level with their CVD patients, shown in Supplementary File 2.

Reviewer #3 (Recommendations for the authors):

1. As described in the public review, I feel the current version of the manuscript does not quite align at places in the abstract, introduction, and discussion with the lack of lifestyle data, which would encompass several key potential confounders. Without it, it seems likely that there is a high risk of substantial confounding. It would be helpful if the authors adjusted the language to more accurately reflect this throughout, such as removing allusions to causal inference and tempering statements about adjustment for confounders where appropriate.

Thank you for the comment. We have now modified the text throughout, by removing causal terms. To explore the potential impact from lifestyle factors, we performed an additional analysis excluding individuals with a history of alcoholic cirrhosis of liver or COPD, as proxies for heavy drinking or smoking, and found similar results (Table added as Supplementary File 1h).

In Abstract

Page 3, remove “halted causal inferences” and replaced with: “The association between cardiovascular disease (CVD) and selected psychiatric disorders has frequently been suggested while the potential role of familial factors and comorbidities in such association has rarely been investigated.”

Page 3, replaced “increased” with “higher”.

In Introduction, Page 5-6:

Removed “firmly”;

Replaced “a rapid rise” to “subsequent risk of”;

Replaced “attributed to” to “explained by”;

Remove “comprehensively”;

In Method, Page 10:

“To account for potential impact of unmeasured confounding due to lifestyle factors, we performed a sensitivity analysis excluding individuals with a history of alcoholic cirrhosis of liver (ICD-10 code K703) or chronic obstructive pulmonary disease (COPD, ICD-10 code J44), as proxies for heavy drinking or smoking.”

In Discussion, Page 14:

“The associations remained similar after excluding individuals with liver cirrhosis and COPD (Supplementary Table S8), as proxies for heavy alcohol consumption and smoking.”

Page 16-17:

“although we found similar results with and without excluding individuals with a history of liver cirrhosis or COPD, as proxies for heavy drinking or smoking (Supplementary File 1h). We did not have direct access to hazardous behaviors that could potentially modify this association, and therefore cannot exclude the possibility of residual confounding.”

In conclusion,

Page 21: “Using a large population-based sibling-controlled cohort with up to thirty years of followup, we found patients with CVD are at elevated risk of newly diagnosed psychiatric disorder, independent of familial background shared between siblings, history of somatic diseases, and other cardiovascular comorbidities. The results further indicate higher cardiovascular mortality among CVD patients with subsequent psychiatric comorbidities, providing evidence for increased surveillance of psychiatric comorbidity among newly diagnosed patients with CVD.”

2. One of the main findings is that psychiatric disorder comorbidity diagnosed after cardiovascular disease diagnosis was associated with an increased risk of CVD-related mortality (as shown in Figure 4). There needs to be more discussion of the potential relevance of cardiovascular disease or psychiatric disorder subtype in this relationship, both in the results and the Discussion sections. Intuitively, it would be expected that more severe cardiovascular diseases are associated with higher stress and a greater risk of psychiatric disorders. As such, the greater rate of mortality in those diagnosed with psychiatric disorders may largely be reflective of the initial cardiovascular diagnosis rather than having much to do with the psychiatric disorder diagnosis. Supplementary Figure 4 suggests that different subtypes of cardiovascular disease may have different relationships between psychiatric disorder diagnosis and survival rate, but this doesn't appear to be touched on at all in the results or the discussion.

Thank you for the comment. We agree that Supplementary Figure S4 indicates varying degree of compromised survival in relation to psychiatric disorders for different types of CVD.

We have now elaborated this in Results (Page 13) and Discussion (Page 15).

In Results, Page 13:

“The compromised CVD-specific survival differed by type of CVD, and was most pronounced for hypertensive disease, ischemic heart disease, and arrhythmia/conduction disorder compared to other CVDs (Figure 4 —figure supplement 2).”

In Discussion, Page 15:

“A compromised survival from CVD cause was indeed observed among most patients with common types of first CVD diagnosis and comorbid with psychiatric disorder, in particular among patients with hypertensive disease, ischemic heart disease, and arrhythmia/conduction disorder. Thus, particular clinical attention is needed for CVD patients with comorbid psychiatric disorders, particularly alcohol or drug misuse or psychotic disorders.”

3. Relatedly, could you please present similar analyses to Supplementary Figure 4 showing different survival curves by psychiatric subtype instead of cardiovascular subtype?

Thank you for the suggestion. We added, as suggested, a Figure 4 —figure supplement 3, showing the survival curves according to types of comorbid psychiatric disorder. A compromised survival was noted among CVD patients comorbid with non-affective and affective psychotic disorders, as well as alcohol or drug misuse.

We have now added this new analysis in Methods (10), Results (Page 13) and Discussion (Page 15).

In Methods, Page 10:

“We estimated the survival curves by types of first CVD types as well as by types of psychiatric comorbidities.”

In Results, Page 13:

“When studying categories of psychiatric disorders, we found that the compromised survival among CVD patients was confined to those with comorbid non-affective and affective psychotic disorders, as well as alcohol or drug misuse (Figure 4 —figure supplement 3).”

In Discussion, Page 15:

“Thus, particular clinical attention is needed for CVD patients with comorbid psychiatric disorders, particularly alcohol or drug misuse or psychotic disorders.”

https://doi.org/10.7554/eLife.80143.sa2

Article and author information

Author details

  1. Qing Shen

    1. Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    2. Centre of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavík, Iceland
    Contribution
    Conceptualization, Formal analysis, Investigation, Visualization, Methodology, Writing - original draft, Writing – review and editing
    For correspondence
    qing.shen@ki.se
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7214-4797

  2. Huan Song

    1. Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    2. Centre of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavík, Iceland
    3. West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, China
    4. Medical Big Data Center, Sichuan University, Chengdu, China
    Contribution
    Conceptualization, Investigation, Methodology, Writing – review and editing
    Competing interests
    No competing interests declared

  3. Thor Aspelund

    Centre of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavík, Iceland
    Contribution
    Investigation, Methodology, Writing – review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7998-5433

  4. Jingru Yu

    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    Contribution
    Data curation, Investigation, Writing – review and editing
    Competing interests
    No competing interests declared

  5. Donghao Lu

    1. Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    2. West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, China
    3. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, United States
    Contribution
    Investigation, Writing – review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4186-8661

  6. Jóhanna Jakobsdóttir

    Centre of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavík, Iceland
    Contribution
    Investigation, Writing – review and editing
    Competing interests
    No competing interests declared

  7. Jacob Bergstedt

    Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    Contribution
    Investigation, Writing – review and editing
    Competing interests
    No competing interests declared

  8. Lu Yi

    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    Contribution
    Investigation, Writing – review and editing
    Competing interests
    No competing interests declared

  9. Patrick Sullivan

    1. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    2. Departments of Genetics and Psychiatry, University of North Carolina, Chapel Hill, United States
    Contribution
    Funding acquisition, Investigation, Writing – review and editing
    Competing interests
    No competing interests declared

  10. Arvid Sjölander

    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    Contribution
    Investigation, Methodology, Writing – review and editing
    Competing interests
    No competing interests declared

  11. Weimin Ye

    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    Contribution
    Resources, Data curation, Writing – review and editing
    Competing interests
    No competing interests declared

  12. Katja Fall

    1. Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    2. Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden
    Contribution
    Investigation, Methodology, Writing – review and editing
    Competing interests
    No competing interests declared

  13. Fang Fang

    Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    Contribution
    Conceptualization, Supervision, Funding acquisition, Investigation, Methodology, Writing – review and editing
    Contributed equally with
    Unnur Valdimarsdóttir
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3310-6456

  14. Unnur Valdimarsdóttir

    1. Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    2. Centre of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavík, Iceland
    3. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, United States
    Contribution
    Conceptualization, Supervision, Funding acquisition, Investigation, Methodology, Writing – review and editing
    Contributed equally with
    Fang Fang
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5382-946X

Funding

EU Horizon 2020 Research and Innovation Action Grant (CoMorMent,847776)

  • Patrick Sullivan

Grant of Excellence, Icelandic Research Fund (163362-51)

  • Unnur Valdimarsdóttir

European Research Council (Consolidator Grant StressGene,726413)

  • Unnur Valdimarsdóttir

Swedish Research Council (D0886501)

  • Patrick Sullivan

National Institute of Mental Health (R01 MH123724)

  • Patrick Sullivan

The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.

Ethics

The study was approved by the Ethical Vetting Board in Stockholm, Sweden (DNRs 2012/1814-31/4 and 2015/1062-32). Informed consent to each participant was waived by Swedish law in nationwide registry data.

Senior Editor

  1. Eduardo Franco, McGill University, Canada

Reviewing Editor

  1. Prabhat Jha, University of Toronto, Canada

Reviewer

  1. Rajini Nagrani, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Germany

Publication history

  1. Received: May 10, 2022
  2. Preprint posted: June 27, 2022 (view preprint)
  3. Accepted: October 20, 2022
  4. Accepted Manuscript published: October 21, 2022 (version 1)
  5. Version of Record published: December 2, 2022 (version 2)

Copyright

© 2022, Shen et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 504
    Page views
  • 101
    Downloads
  • 2
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Qing Shen
  2. Huan Song
  3. Thor Aspelund
  4. Jingru Yu
  5. Donghao Lu
  6. Jóhanna Jakobsdóttir
  7. Jacob Bergstedt
  8. Lu Yi
  9. Patrick Sullivan
  10. Arvid Sjölander
  11. Weimin Ye
  12. Katja Fall
  13. Fang Fang
  14. Unnur Valdimarsdóttir
(2022)
Cardiovascular disease and subsequent risk of psychiatric disorders: a nationwide sibling-controlled study
eLife 11:e80143.
https://doi.org/10.7554/eLife.80143

Categories and tags

Research organism

Further reading

    1. Epidemiology and Global Health
    2. Medicine

    Health: Understanding the links between cardiovascular and psychiatric conditions

    Sonali Amarasekera, Prabhat Jha
    Insight

    Individuals recently diagnosed with a cardiovascular disease are at higher risk of developing a mental illness, with mortality increasing when both conditions are present.

    1. Epidemiology and Global Health

    Associations of ABO and Rhesus D blood groups with phenome-wide disease incidence: A 41-year retrospective cohort study of 482,914 patients

    Peter Bruun-Rasmussen, Morten Hanefeld Dziegiel ... Søren Brunak
    Research Article Updated

    Background:

    Whether natural selection may have attributed to the observed blood group frequency differences between populations remains debatable. The ABO system has been associated with several diseases and recently also with susceptibility to COVID-19 infection. Associative studies of the RhD system and diseases are sparser. A large disease-wide risk analysis may further elucidate the relationship between the ABO/RhD blood groups and disease incidence.

    Methods:

    We performed a systematic log-linear quasi-Poisson regression analysis of the ABO/RhD blood groups across 1,312 phecode diagnoses. Unlike prior studies, we determined the incidence rate ratio for each individual ABO blood group relative to all other ABO blood groups as opposed to using blood group O as the reference. Moreover, we used up to 41 years of nationwide Danish follow-up data, and a disease categorization scheme specifically developed for diagnosis-wide analysis. Further, we determined associations between the ABO/RhD blood groups and the age at the first diagnosis. Estimates were adjusted for multiple testing.

    Results:

    The retrospective cohort included 482,914 Danish patients (60.4% females). The incidence rate ratios (IRRs) of 101 phecodes were found statistically significant between the ABO blood groups, while the IRRs of 28 phecodes were found statistically significant for the RhD blood group. The associations included cancers and musculoskeletal-, genitourinary-, endocrinal-, infectious-, cardiovascular-, and gastrointestinal diseases.

    Conclusions:

    We found associations of disease-wide susceptibility differences between the blood groups of the ABO and RhD systems, including cancer of the tongue, monocytic leukemia, cervical cancer, osteoarthrosis, asthma, and HIV- and hepatitis B infection. We found marginal evidence of associations between the blood groups and the age at first diagnosis.

    Funding:

    Novo Nordisk Foundation and the Innovation Fund Denmark

    1. Epidemiology and Global Health
    2. Genetics and Genomics

    Polygenic risk scores for the prediction of common cancers in East Asians: A population-based prospective cohort study

    Peh Joo Ho, Iain BeeHuat Tan ... Jingmei Li
    Research Article

    Background: To evaluate the utility of polygenic risk scores (PRS) in identifying high-risk individuals, different publicly available PRS for breast (n=85), prostate (n=37), colorectal (n=22) and lung cancers (n=11) were examined in a prospective study of 21,694 Chinese adults.

    Methods: We constructed PRS using weights curated in the online PGS Catalog. PRS performance was evaluated by distribution, discrimination, predictive ability, and calibration. Hazard ratios (HR) and corresponding confidence intervals [CI] of the common cancers after 20 years of follow-up were estimated using Cox proportional hazard models for different levels of PRS.

    Results: A total of 495 breast, 308 prostate, 332 female-colorectal, 409 male-colorectal, 181 female-lung and 381 male-lung incident cancers were identified. The area under receiver operating characteristic curve for the best performing site-specific PRS were 0.61 (PGS000873, breast), 0.70 (PGS00662, prostate), 0.65 (PGS000055, female-colorectal), 0.60 (PGS000734, male-colorectal) and 0.56 (PGS000721, female-lung), and 0.58 (PGS000070, male-lung), respectively. Compared to the middle quintile, individuals in the highest cancer-specific PRS quintile were 64% more likely to develop cancers of the breast, prostate, and colorectal. For lung cancer, the lowest cancer-specific PRS quintile was associated with 28-34% decreased risk compared to the middle quintile. In contrast, the hazard ratios observed for quintiles 4 (female-lung: 0.95 [0.61-1.47]; male-lung: 1.14 [0.82-1.57]) and 5 (female-lung: 0.95 [0.61-1.47]) were not significantly different from that for the middle quintile.

    Conclusions: Site-specific PRSs can stratify the risk of developing breast, prostate, and colorectal cancers in this East Asian population. Appropriate correction factors may be required to improve calibration.

    Funding This work is supported by the National Research Foundation Singapore (NRF-NRFF2017-02), PRECISION Health Research, Singapore (PRECISE) and the Agency for Science, Technology and Research (A*STAR). WP Koh was supported by National Medical Research Council, Singapore (NMRC/CSA/0055/2013). CC Khor was supported by National Research Foundation Singapore (NRF-NRFI2018-01). Rajkumar Dorajoo received a grant from the Agency for Science, Technology and Research Career Development Award (A*STAR CDA - 202D8090), and from Ministry of Health Healthy Longevity Catalyst Award (HLCA20Jan-0022). The Singapore Chinese Health Study was supported by grants from the National Medical Research Council, Singapore (NMRC/CIRG/1456/2016) and the U.S. National Institutes of Health [NIH] (R01 CA144034 and UM1 CA182876).